An interventional study of Subdermal Implant in Nasolabial Folds, sponsored by Merz North America, Inc.. Recruiting at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Merz North America, Inc. (part of Merz Pharma) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to confirm the long-term safety, effectiveness, and degradation profile of RADIESSE® Injectable Implant for the correction of moderate to severe nasolabial folds (NLFs) in Chinese adults. Eligible participants will receive treatment with RADIESSE® Injectable Implant in both NLFs and may receive an optional touch-up treatment at Month 1 at investigator's discretion. Participants will be followed for up to 24 months after last treatment.
Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive a single injection of RADIESSE® administered to both NLFs on Day 1. Participants may receive an optional touch-up injection at Month 1 following the initial treatment at investigator's discretion. RADIESSE® will be administered according to the current product labelling and instruction for use.
Device: Subdermal Implant
Participants will receive treatment with RADIESSE® Injectable Implant.
Also known as: Calcium Hydroxylapatite (CaHA)
Percentage of Participants Achieving at Least a 1-point Improvement in Both NLFs From Baseline to Month 6 after Last Treatment on the Wrinkle Severity Rating Scale (WSRS), as Assessed Live by the Treating Investigator
Severity of the NLFs was assessed and measured using the 5-point WSRS, where 1=absent and 5=extreme. A lower score indicates better outcome.
Time frame: At Month 6 after last treatment
Percentage of Participants Achieving Improvement (Score of 1, 2, 3) on the Investigator Global Aesthetic Improvement Scale (iGAIS) at Month 6 After Last Treatment, as Assessed Live by the Treating Investigator
The iGAIS is an assessment grading scale where the treating investigator describes the degree of improvement in facial appearance according to the GAIS, a 5-point scale ranging from 'Very Much Improved' (1) to 'Worse' (5). The investigator will be asked to rate the NLFs and select the rating that best applies when asked "What is the overall impression of aesthetic change of the participants NLFs due to treatment, compared to the pretreatment photograph". Improvement is defined as a rating of +1, +2, or +3. The higher the iGAIS score, the greater the improvement.
Time frame: At Month 6 after last treatment
Percentage of Participants Achieving Improvement (Score of 1, 2, 3) on the Participant Global Aesthetic Improvement Scale (pGAIS) at Month 6 After Last Treatment, as Assessed Live by Participant
The pGAIS is a self-assessment grading scale where the participant independently describes the degree of improvement in facial appearance according to the GAIS, a 5-point scale ranging from 'Very Much Improved' (1) to 'Worse' (5). Participants will be asked to rate the NLFs and select the rating that best applies when asked "What is the overall impression of aesthetic change of your NLFs due to treatment, compared to the pretreatment photograph?" Improvement is defined as a rating of +1, +2, or +3. The higher the pGAIS score, the greater the improvement.
Time frame: At Month 6 after last treatment
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.